UK’s MHRA Enhances Risk-Based Inspection Process
This article was originally published in The Gold Sheet
Executive Summary
MHRA has begun sifting data with powerful software to help the British inspectorate set GMP inspection priorities – and even to alert companies to emerging issues so they can take steps to stay out of trouble. Other agencies show interest in using the system, which would enable data sharing that could make it even more sensitive and confident in its risk analysis.
You may also be interested in...
FDA’s New ‘Site Engagement’ Program Aims To Avert Quality-Related Drug Shortages
US FDA office that surveils drug manufacturing facilities invites sites on the cusp of failure for “engagements” in which they talk about how to turn things around. The agency says there’s no pressure – these site engagements aren’t enforcement actions and they’re completely voluntary.
Mutual Reliance Blossoming Among FDA, EMA, Other Inspectorates
FDA, EMA and other agencies are increasingly relying on each others' inspection results in an effort to spread their inspectional resources throughout the furthest corners of the globe. Inspection coordination remains somewhat ad hoc, with EMA keeping a spreadsheet for some and PIC/S enabling others. EMA's EudraGMP database is touted as a coordination hub.
More Change With Less Hoopla To FDA Out-Of-Specification Investigations Policy
Agency’s revised OOS guidance clarifies positions on outlier test results, averaging of HPLC results and some finer points around OOS questions. These could marginally improve compliance but won’t impact industry with nearly the force of the original 2006 guidance or the 1993 court ruling that preceded it.